42,411 results match your criteria Lymphoma Non-Hodgkin


Increasing use of immunotherapy and prolonged survival among younger patients with primary CNS lymphoma: a population-based study.

Acta Oncol 2019 Apr 17:1-10. Epub 2019 Apr 17.

a Institute of Neurology , Medical University of Vienna , Vienna , Austria.

Background: Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups.

Material And Methods: Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/0284186X.2019.1599137DOI Listing

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later.

Drugs R D 2019 Apr 16. Epub 2019 Apr 16.

Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, 93-510, Lodz, Poland.

Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity. It exerts its anti-neoplastic action mainly via the inhibition of the nuclear factor-κB pathway components associated with cell proliferation, apoptosis, and angiogenesis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40268-019-0269-9DOI Listing

Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma.

Support Care Cancer 2019 Apr 15. Epub 2019 Apr 15.

Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, 91320, USA.

Purpose: Limited information is available regarding elderly patients experiencing febrile neutropenia (FN). This study evaluated FN-related care among elderly cancer patients who received high/intermediate FN-risk chemotherapy and experienced ≥ 1 FN episodes.

Methods: We used Medicare data to identify patients aged ≥ 66 years who initiated high/intermediate FN-risk chemotherapy between 1 January 2008 and 31 August 2015 to treat breast cancer (BC), lung cancer (LC), or non-Hodgkin lymphoma (NHL) and had ≥ 1 FN episodes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04795-0DOI Listing

Image-guided Fine Needle Aspiration Cytology of Intrathoracic Lesions.

J Cytol 2019 Apr-Jun;36(2):106-110

Department of Pulmonary Medicine, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India.

Background: Percutaneous, image-guided transthoracic fine needle aspiration cytology (TTFNAC) is a rapid, yet accurate, and well-established diagnostic method used in the cytological evaluation of intrathoracic lesions. The study was done to determine the utility of image-guided TTFNAC in diagnosis of intrathoracic lesions.

Subjects And Methods: A retrospective analysis of all cases who underwent image-guided TTFNAC of a suspected intrathoracic lesion, in a tertiary care hospital was done over a period of 3 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/JOC.JOC_187_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425786PMC

Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib.

Clin Lymphoma Myeloma Leuk 2019 Mar 11. Epub 2019 Mar 11.

Division of Hematology/Oncology, University of Virginia, Charlottesville, VA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2019.03.001DOI Listing

Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma.

Ann Hematol 2019 Apr 15. Epub 2019 Apr 15.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-Hodgkin lymphoma for which standard treatment has yet to be established. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a suitable consolidation strategy for patients who respond to induction chemotherapy. The purpose of this study was to compare the outcome and toxicity profile of the combination of busulfan, cyclophosphamide, and etoposide (BuCyE) with that of the combination of thiotepa, busulfan, and cyclophosphamide (TBC) as conditioning regimens of upfront ASCT for consolidation therapy in PCNSL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-019-03667-1DOI Listing

Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report.

BMC Cancer 2019 Apr 15;19(1):355. Epub 2019 Apr 15.

Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Background: Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) that often affects men over the age of 60. Systemic metastasis of MCL to eyes is rare and intraocular involvement is even rarer, which usually affects the choroid and iris. To the best of our knowledge, ciliary body metastasis of systemic MCL has not been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-5530-7DOI Listing

Postchemotherapy Histiocyte-Rich Pseudotumor of the Spleen Simulating Residual Disease in a Patient With Non-Hodgkin Lymphoma on FDG PET/CT.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

the Department of Hematology, Soroka University Medical Center, Beer-Sheva, Israel. Affiliated to Ben Gurion University of the Negev, Faculty of Health Sciences.

A 64-year-old man was treated with multiagent chemotherapy owing to high-grade non-Hodgkin lymphoma presenting as a bulky disease involving the spleen. Interim and posttreatment sequential FDG PET/CT scans revealed a residual splenic mass showing markedly intense FDG uptake suspected of a residual viable lymphoma. To definitely decide about the appropriate treatment, a laparoscopic splenectomy was performed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002568DOI Listing

68Ga CXCR-4 PET/CT Imaging in an Atypical Case of Extramedullary Plasmacytoma Mimicking as Renal Cell Carcinoma.

Clin Nucl Med 2019 Apr 12. Epub 2019 Apr 12.

Nephrology Post Graduate Institute of Medical Education and Research, Chandigarh, India.

Multiple-myeloma (MM) is a malignant plasma cell proliferation disorder and the second most common blood malignancy after non-Hodgkin lymphoma. The chemokine (CXCR-4) receptor analogues are the newer agents being postulated for myeloma imaging and have shown good diagnostic performance. We report a case of plasmacytoma with suspicious renal cell carcinoma, in whom Ga CXCR-4 PET/CT revealed tracer-avid lesion in the left perinephric region. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002574DOI Listing

Investigation of lymphoid lesions of the Head and Neck using combined fine needle aspiration cytology and flow cytometry: accuracy and pitfalls.

Cytopathology 2019 Apr 15. Epub 2019 Apr 15.

Cytology Department, Sullivan Nicolaides Pathology, 24 Hurworth St, Bowen Hills, 4006.

Objective: We reviewed the diagnostic utility of combined fine needle aspiration cytology (FNAC) and flow cytometry (FC) in the diagnosis of lymphoid lesions of the head and neck.

Method: 1402 patients with combined FNAC-FC reports were correlated with follow-up information. Rapid on-site evaluation (ROSE) of cytological specimens was performed in 52% of cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12706DOI Listing

Burkitt Lymphoma of the Duodenum: An Uncommon Phenomenon.

Case Rep Gastrointest Med 2019 7;2019:7313706. Epub 2019 Mar 7.

Internal Medicine, Richmond University Medical Center, Staten Island, NY 10310, USA.

Burkitt lymphoma is an aggressively growing tumor commonly found in African children, involving the jaw and facial bones. Most non-Hodgkin lymphoma tumors involve extra nodal sites like the nervous system and gastrointestinal tract. A rare variant of this type of lymphoma is found in immunocompromised patients specifically in the gastrointestinal tract with accompanying gastrointestinal symptoms. Read More

View Article

Download full-text PDF

Source
https://www.hindawi.com/journals/crigm/2019/7313706/
Publisher Site
http://dx.doi.org/10.1155/2019/7313706DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6431491PMC
March 2019
5 Reads

Extranasal extranodal NK/T cell lymphoma: A post-transplantation lymphoproliferative disease.

Int Wound J 2019 Apr 14. Epub 2019 Apr 14.

Department of Dermatology, Medical Faculty, Ege University, Izmir, Turkey.

Extranodal NK/T cell lymphoma (ENKTL) is a rare form of non-Hodgkin lymphoma. It mostly occurs in the upper respiratory tract. Cutaneous involvement can be seen among the extranasal ENKTLs. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/iwj.13126
Publisher Site
http://dx.doi.org/10.1111/iwj.13126DOI Listing
April 2019
7 Reads

Hepatitis C Virus Infection and Non-Hepatocellular Malignancies in the DAA Era: A Systematic Review and Meta-Analysis.

Liver Int 2019 Apr 15. Epub 2019 Apr 15.

Internal Medicine and Hepatology Unit, University of Salerno, Salerno, Italy.

Background And Aims: Direct antiviral agents have greatly improved therapeutic options for chronic hepatitis C. Indeed, former "difficult-to-treat" patients can now be treated and can achieve sustained response. HCV is associated with hepatocellular carcinoma and with B-cell non-Hodgkin lymphoma(B-NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/liv.14119DOI Listing

The accuracy of diagnosing Burkitt lymphoma in serous effusion specimen: a cytological-histological correlation with ancillary studies.

Cytopathology 2019 Apr 15. Epub 2019 Apr 15.

Department of pathology, West China Hospital of Sichuan University, Chengdu, 610041, China.

Objective: The objective of this study is to evaluate the effectiveness of diagnosing Burkitt lymphoma (BL) in serous effusion (SE) specimen and summarize the characteristics of BL in SE. We also assess the utility of a germinal centre-associated marker, LMO2, in the differential diagnosis of BL in SE specimen.

Methods: Eleven cases of malignant SE caused by BL were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cyt.12707DOI Listing

Risk factors for death and survival in paraneoplastic pemphigus associated with hematologic malignancies in adults.

J Am Acad Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Assistance Publique-Hôpitaux de Paris, Département de Dermatologie, Hôpital Saint-Louis, Paris, France; Université Paris-Diderot, Sorbonne Paris Cité, Paris, France. Electronic address:

Background: Paraneoplastic pemphigus (PNP) occurs more often in patients with hematologic malignancies (HMs) than in patients with solid cancer. Lung bronchiolitis obliterans (BO) is a severe complication of PNP.

Objective: To determine the precise clinical and biologic features of HM-associated PNP and identify factors associated with mortality and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.03.043DOI Listing

Association of red blood cell distribution width and outcomes in patients with mantle cell lymphoma.

Cancer Med 2019 Apr 13. Epub 2019 Apr 13.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.

Red blood cell distribution width (RDW), which measures the range of variation of red blood cell volume, has been explored as a prognostic factor in multiple types of cancer. However, the role of RDW in mantle cell lymphoma (MCL), a rare type of non-Hodgkin lymphoma with poor outcomes, remains to be determined. Therefore, we investigated the prognostic role of RDW in MCL. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.2155
Publisher Site
http://dx.doi.org/10.1002/cam4.2155DOI Listing
April 2019
6 Reads

Bendamustine for patients with indolent B cell lymphoproliferative malignancies including chronic lymphocytic leukaemia - an updated meta-analysis.

Br J Haematol 2019 Apr 13. Epub 2019 Apr 13.

Tel Aviv University, Tel Aviv.

The question of which chemotherapy induction provides the best results for indolent lymphoma patients is yet unanswered. Different regimens have been compared, none of which has been shown to improve overall survival. The use of bendamustine is growing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15901DOI Listing
April 2019
2 Reads

Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.

Blood Adv 2019 Apr;3(8):1230-1243

Division of Cancer Medicine, Department of Cellular Therapy, and.

T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-NHL) patients. However, a subset of patients who relapse after CD19CAR T-cell therapy have outgrowth of CD19 tumor cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018029678DOI Listing
April 2019
2 Reads

Non-Hodgkin Lymphoma in the Middle East Is Characterized by Low Incidence Rates With Advancing Age.

J Glob Oncol 2019 Apr(5):1-10

3 Shorsh General and Hiwa Cancer Hospitals, Sulaimaniyah, Iraq.

Purpose: In the Middle East, incidence rate ratios (IRRs) of non-Hodgkin lymphoma (NHL) to Hodgkin lymphoma (HL) are more than 50% lower than the United States.

Materials And Methods: Age-specific incidence rates (ASIRs), age-adjusted incidence rates (AAIRs), and IRRs of NHL:HL were compared using the cancer registries of Iraq, Jordan, Saudi Arabia, and US SEER.

Results: The NHL AAIR (95% CI) per 100,000 population was 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.18.00241DOI Listing
April 2019
1 Read

Seroepidemiological analysis and literature review of the prevalence of Epstein-Barr virus and herpesvirus infections in pediatric cases with non-Hodgkin lymphoma in Central Europe.

Pediatr Blood Cancer 2019 Apr 12:e27752. Epub 2019 Apr 12.

Department of Pediatric Hematology and Oncology, Justus Liebig University Giessen, Giessen, Germany.

Background: Epstein-Barr virus (EBV) is linked to a variety of malignancies; most endemic Burkitt lymphoma (BL) harbor EBV, whereas only a subset of the cases of sporadic BL is EBV positive.

Procedure: We retrospectively determined the herpesvirus seroprevalence at the time of diagnosis in pediatric non-Hodgkin lymphoma (NHL) patients enrolled in NHL-BFM (Berlin-Frankfurt-Muenster) studies. We accessed the seroepidemiological data from 1147 patients that became available during 1990-2007. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.27752DOI Listing
April 2019
1 Read

Non-Hodgkin's lymphoma with extensive emperipolesis mimicking Rosai-Dorfman disease: A rare case report.

Indian J Pathol Microbiol 2019 Apr-Jun;62(2):319-322

Department of Pathology, Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India.

Emperipolesis is the hallmark finding for Rosai-Dorfman disease. Till now many studies in literatures have shown emperipolesis as a finding in other benign as well as malignant conditions. Very few cases of malignant lymphoma have this phenomenon. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/IJPM.IJPM_409_18DOI Listing
April 2019
1 Read

Physical torment: A predisposition for diffuse B-cell lymphoma.

J Oral Maxillofac Pathol 2019 Feb;23(Suppl 1):17-22

Department of Oral and Maxillofacial Surgery, GSL Dental College, Rajahmundry, Andhra Pradesh, India.

Lymphomas of the oral cavity are rare and represent only 3%-5% of all lymphomas. Diffuse large B-cell lymphomas (DLBCLs) are a heterogeneous group of tumor and the most common type of all non-Hodgkin's lymphomas (NHLs). They mostly arise from soft tissue as asymptomatic swelling and involvement of jaw bones is infrequent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jomfp.JOMFP_7_18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421932PMC
February 2019
1 Read

Monocytoid B cell lymphoma: A case report and evaluation.

J Oral Maxillofac Pathol 2019 Feb;23(Suppl 1):2-6

Department of Oral and Maxillofacial Pathology and Microbiology, Sri Guru Ram Das Institute of Dental Sciences and Research, Amritsar, Punjab, India.

Lymphomas are a group of malignant blood cell tumors that develop from lymphocytes. Two main categories of lymphomas are Hodgkin and non-Hodgkin lymphomas (NHL), of which 90% are of the NHL type. The objectives of classifying is to help in the identification of homogenous group of well-defined entities and facilitating the recognition of uncommon diseases that further require classification as it affects prognosis and therapeutic implications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jomfp.JOMFP_101_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421917PMC
February 2019
5 Reads

Acalabrutinib for Mantle Cell Lymphoma.

Blood 2019 Apr 9. Epub 2019 Apr 9.

Division of Hematology, Mayo Clinic, United States.

Mantle cell lymphoma (MCL) is a unique type of non-Hodgkin lymphoma (NHL) characterized by the overexpression of cyclin D1. MCL patients typically live years but experience multiple relapses. Acalabrutinib (Acala) is a novel second generation oral Bruton's tyrosine kinase (BTK) inhibitor approved by the US FDA for relapsed MCL based on a clinical trial demonstrating an overall response rate of 81%. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood.2019852368DOI Listing
April 2019
3 Reads

Intermediate-dose cytarabine plus G-CSF as mobilization regimen for newly diagnosed multiple myeloma and heavily pre-treated patients with hematological and non-hematological malignancies.

Transfus Apher Sci 2019 Mar 29. Epub 2019 Mar 29.

Centro de Hematologia do Vale, Rua Euclides Miragaia 700, Sala 75 - Centro, São José dos Campos, São Paulo 12245-820, Brazil. Electronic address:

Background: Intermediate-dose cytarabine plus G-CSF has recently emerged as safe and effective mobilization regimen for heavily pre-treated patients with lymphoid malignancies. We prospectively tested this regimen in patients referred to our center in order to collect enough stem cells for hematopoietic rescue in autologous transplantation (auto-HSCT).

Study Design And Methods: cytarabine (1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.transci.2019.03.018DOI Listing
March 2019
1 Read

Hepatitis C virus infection and cholangiocarcinoma: An insight into epidemiological evidences and hypothetical mechanisms of oncogenesis.

Am J Pathol 2019 Apr 3. Epub 2019 Apr 3.

Baylor Scott & White Digestive Disease Research Center, Temple, TX, USA; Division of Research, Central Texas Veterans Health Care System, Temple, TX, USA. Electronic address:

Hepatitis C Virus (HCV) infection is a global public health problem since it is a main cause of liver cirrhosis and hepatocellular carcinoma (HCC). This human oncogenic virus is also associated with the development of non-Hodgkin lymphoma and cholangiocarcinoma (CCA). The association between HCV infection and CCA has been examined in a number of epidemiological studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2019.01.018DOI Listing
April 2019
3 Reads

Microfluidic chip technology applied to fine-needle aspiration cytology samples for IGH clonality assessment.

Diagn Cytopathol 2019 Apr 5. Epub 2019 Apr 5.

Department of Public Health, University of Naples "Federico II", Naples, Italy.

Background: Most cases of non-Hodgkin lymphoma (NHL) can be diagnosed using a combination of fine-needle cytology (FNC) and flow cytometry together with immunoglobulin light chain restriction and/or specific phenotypic profiles. However, 5%-15% of B-cell NHLs lack these specific diagnostic features. In such cases, the diagnosis of NHL may be supported by molecular clonality testing based on the immunoglobulin heavy chain (IGH) assay of clonality by polyacrylamide heteroduplex analysis or by automated capillary electrophoresis via GeneScan analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24184DOI Listing
April 2019
1 Read

Primary Mediastinal Large B-Cell Lymphoma in a Child Presenting With Superior Mediastinal Syndrome and Chylous Pleural and Pericardial Effusion.

J Pediatr Hematol Oncol 2019 Apr 3. Epub 2019 Apr 3.

Departments of Pediatric Oncology.

Primary mediastinal (thymic) large B-cell lymphoma is an aggressive B-cell lymphoma. It comprises <3% of all pediatric non-Hodgkin lymphomas (NHLs). Primary mediastinal (thymic) large B-cell lymphoma usually presents with serous pleural effusion, but presentation with chylous pleural and pericardial effusions is rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MPH.0000000000001472DOI Listing
April 2019
3 Reads

Epidemiology, Tumor Characteristics, and Survival in Patients With Primary Pancreatic Lymphoma: A Large Population-based Study Using the SEER Database.

Am J Clin Oncol 2019 Apr 3. Epub 2019 Apr 3.

Department of Hematology and Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH.

Introduction: Primary pancreatic lymphoma (PPL) is an extranodal manifestation of non-Hodgkin lymphoma originating in the pancreas, which constitutes <1% of all pancreatic neoplasms. Because of the rarity of the disease, most data on PPL are derived from case reports and small case series. To provide better insight into the epidemiology, treatment, and outcomes of these patients, we conducted an analysis of patients with PPL from the Surveillance, Epidemiology and End Results (SEER) database, which is presented in this study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000544DOI Listing
April 2019
2 Reads

Clinical characteristics and prognosis associated with multiple primary malignant tumors in non-Hodgkin lymphoma patients.

Tumori 2019 Apr 4:300891619839475. Epub 2019 Apr 4.

1 Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

Objective:: Patients with non-Hodgkin lymphoma (NHL) occasionally present with multiple primary malignant tumors (MPMTs). This study aimed to determine the clinical characteristics, survival, and risk factors of these patients.

Methods:: The median follow-up of 92 patients was 13. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0300891619839475
Publisher Site
http://dx.doi.org/10.1177/0300891619839475DOI Listing
April 2019
4 Reads

Existing and Emerging Therapies for Cutaneous T-Cell Lymphoma.

J Cutan Med Surg 2019 Apr 3:1203475419840629. Epub 2019 Apr 3.

1 Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.

Cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of non-Hodgkin lymphomas characterized by an infiltration of malignant monoclonal T lymphocytes into the skin. Mycosis fungoides (MF), the most common subtype, and the rarer Sézary syndrome (SS), are considered the classical forms of CTCL, which, because of a varying presentation and lack of genetic and immunophenotypical markers, can often have a delayed diagnosis. With skin-directed topical treatment being the mainstay of therapy in the early stages, there is an absence of long-term curative therapies for advanced disease. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475419840629
Publisher Site
http://dx.doi.org/10.1177/1203475419840629DOI Listing
April 2019
7 Reads

3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.

J Med Chem 2019 Apr 17. Epub 2019 Apr 17.

Laboratory of Growth Regulators , Palacký University and Institute of Experimental Botany, The Czech Academy of Sciences , Šlechtitelů 27 , 783 71 Olomouc , Czech Republic.

Cyclin-dependent kinases are therapeutic targets frequently deregulated in various cancers. By convenient alkylation of the 5-sulfanyl group, we synthesized 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2) H-pyrazolo[4,3- d]pyrimidines with various substitutions at position 5 with potent antiproliferative activity in non-Hodgkin lymphoma cell lines. The most potent derivative 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acs.jmedchem.9b00189DOI Listing
April 2019
2 Reads

Evaluation of the impact of cachexia on clinical outcomes in aggressive lymphoma.

Br J Haematol 2019 Apr 2. Epub 2019 Apr 2.

Rush University Medical Center, Chicago, IL, USA.

Cancer cachexia is a state of involuntary weight loss and altered body composition triggered by an underlying malignancy. We sought to correlate measures of cachexia with clinical outcomes in aggressive lymphomas and to identify biological pathways involved in the cachexia phenotype for possible druggable targets. Radiographic measures of cachexia were collected in a retrospective cohort of 109 patients with aggressive B-cell lymphoma and followed for clinical outcome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15889DOI Listing
April 2019
3 Reads

Alternative and canonical NF-kB pathways DNA-binding hierarchies networks define Hodgkin lymphoma and Non-Hodgkin diffuse large B Cell lymphoma respectively.

J Cancer Res Clin Oncol 2019 Apr 2. Epub 2019 Apr 2.

Instituto de Medicina Traslacional e Ingeniería Biomédica (IMTIB), CONICET-Instituto Universitario del Hospital Italiano-Hospital Italiano de Buenos Aires, Potosí 4240 C.P., C1183AEG, Buenos Aires, Argentina.

Purpose: Despite considerable evidence that supports the NF-kB role in the immune system and lymphomagenesis, it is unclear whether specific NF-kB dimers control a particular set of genes that account for their biological functions. Our previous work showed that Hodgkin Lymphoma (HL) is unique, among germinal center (GC)-derived lymphomas, with respect to its dependency on Rel-B to survive. In contrast, diffuse large B-Cell lymphoma (DLBCL) including both Activated B-Cell-Like and Germinal Center B-Cell-Like, requires cREL and Rel-A to survive and it is not affected by Rel-B depletion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02909-zDOI Listing
April 2019
2 Reads

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Oncologist 2019 Apr 2. Epub 2019 Apr 2.

Institute of Hematology, University of Bologna, Bologna, Italy

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma subtype, and approximately 50% of the patients are >60 years of age. Patients with relapsed/refractory (rr) disease have a poor prognosis with currently available treatments. Lenalidomide is available in Italy for patients with rrDLBCL based on a local disposition of the Italian Drug Agency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2018-0603DOI Listing
April 2019
7 Reads

Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group.

J Geriatr Oncol 2019 Mar 30. Epub 2019 Mar 30.

Department of Internal Medicine, Chulalongkorn University, Bangkok, Thailand.

Introduction: Peripheral T cell NHL (PTCL) and natural killer/T cell NHL (NKTCL) are relatively rare disorders. Data on clinical presentation, treatment and outcome are limited especially in older age groups.

Methods: We identified 127 patients with PTCL and NKTCL, excluding cutaneous T/NK cell lymphoma, aged over 60 years old from Thailand nationwide multicenter registry. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S18794068183036
Publisher Site
http://dx.doi.org/10.1016/j.jgo.2019.03.016DOI Listing
March 2019
10 Reads

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

JCI Insight 2019 Apr 2;5. Epub 2019 Apr 2.

Background: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on safety and efficacy of autologous CD19-targeted CAR T-cells for these patients; here we report safety and long-term follow-up of CAR T-cell therapy with or without conditioning chemotherapy for patients with R/R CLL and indolent B-cell non-Hodgkin lymphoma (B-NHL).

Methods: We conducted a phase 1 clinical trial investigating CD19-targeted CAR T-cells incorporating a CD28 costimulatory domain (19-28z). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.122627DOI Listing
April 2019
2 Reads

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Lancet Haematol 2019 Mar 29. Epub 2019 Mar 29.

US Oncology and Willamette Valley Cancer Institute, Springfield, OR, USA.

Background: Antibody-drug conjugates (ADCs) polatuzumab vedotin (pola) and pinatuzumab vedotin (pina) showed clinical activity and tolerability in phase 1 trials. The aim of this multicentre, open-label, phase 2 study was to compare rituximab plus pola (R-pola) or pina (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma.

Methods: In this phase 2 randomised study at 39 investigational sites in six countries, patients were randomly assigned (1:1), by use of a dynamic hierarchical randomisation scheme, to receive R-pola or R-pina (375 mg/m rituximab plus 2·4 mg/kg ADCs) every 21 days until disease progression or unacceptable toxicity up to 1 year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(19)30026-2DOI Listing
March 2019
4 Reads

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.

Int Rev Immunol 2019 Mar 31:1-13. Epub 2019 Mar 31.

a Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences , Tehran , Iran.

Radioimmunotherapy (RIT) is a novel strategy for treating non-Hodgkin lymphoma (NHL). Several studies have shown the promising results of using RIT in NHL, which have led to FDA approval for two RIT agents in treating low grade NHL. In spite of these favorable results in low-grade NHL, most of the aggressive or relapsed/refractory NHL subjects experience relapses following RIT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/08830185.2019.1588266DOI Listing
March 2019
1 Read
4.103 Impact Factor

Unraveling Tumor Heterogeneity in an Apparently Monolithic Disease: BCL2 and Other Players in the Genetic Landscape of Nodal Follicular Lymphoma.

Front Med (Lausanne) 2019 15;6:44. Epub 2019 Mar 15.

Unit of Pathology, Department of Medicine and Surgery, University of Insubria, Varese, Italy.

Follicular lymphoma (FL) is the most common form of non-Hodgkin lymphoma in Western countries. Although traditionally considered a well-defined, easy to diagnose lymphoproliferative disorder, in the last few years it has become clear that it is in fact composed of many different clinicopathological entities, encompassing a variegated and complex genetic background. This has led to the inclusion of specific FL variants and separate entities in the latest update of the WHO classification. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmed.2019.00044DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428742PMC
March 2019
1 Read

Difficult-to-treat Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Secondary Central Nervous System Lymphoma.

Cureus 2019 Jan 17;11(1):e3905. Epub 2019 Jan 17.

Internal Medicine, Peterborough City Hospital, Peterborough, GBR.

The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is defined as hyponatremia with inappropriately concentrated urine in a euvolemic patient. SIADH is associated with a wide spectrum of clinical conditions. In the hospital, hyponatremia carries significant mortality with a prolonged duration of inpatient stay. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.3905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426639PMC
January 2019
1 Read

Clinical Significance of Polymorphisms in Immune Response Genes in Hepatitis C-Related Hepatocellular Carcinoma.

Front Microbiol 2019 15;10:475. Epub 2019 Mar 15.

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.

Polymorphisms in the immune response genes can contribute to clearance of hepatitis C virus (HCV) infection but also mediate liver inflammation and cancer pathogenesis. This study aimed to investigate the association of polymorphisms in PD-1 (PDCD1), IFNL3 (IL28B), and TLR2 immune related genes in chronic HCV patients with different hepatic and lymphoproliferative HCV-related diseases. Selected PDCD1, IFNL3, and TLR2 genes were tested by molecular approaches in 450 HCV-positive patients with increasing severity of underlying liver diseases [including chronic infection (CHC), cirrhosis and hepatocellular carcinoma (HCC)], in 238 HCV-positive patients with lymphoproliferative diseases [such as cryoglobulinemia and non-Hodgkin lymphoma (NHL)] and in 94 blood donors (BD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fmicb.2019.00475DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429030PMC
March 2019
1 Read

[Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].

Yakugaku Zasshi 2019 ;139(4):629-633

Department of Pharmacy, Hiroshima University Hospital.

The combination of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin with rituximab (DA-EPOCH-R) is used for non-Hodgkin lymphoma patients. Febrile neutropenia (FN) is a common complication of treatment with myelo-suppressive chemotherapy, so preventing FN is important for maintaining chemotherapy dosage. Recently, pegfilgrastim has been used as the primary prophylaxis of FN in Japan, but there have been few cases reported using pegfilgrastim for the primary prophylaxis in DA-EPOCH-R. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1248/yakushi.18-00101DOI Listing
April 2019
1 Read

Non-Hodgkin lymphoma risk and organophosphate and carbamate insecticide use in the north American pooled project.

Environ Int 2019 Mar 27;127:199-205. Epub 2019 Mar 27.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.

Organophosphates and carbamates have been among the most commonly used insecticides, with both agricultural and residential uses. Previous studies have suggested associations of non-Hodgkin lymphoma (NHL) with some of these chemicals; however, many studies have been limited in their ability to evaluate associations with lymphoma subtypes. We evaluated the use of eleven organophosphate and two carbamate insecticides in association with NHL in the North American Pooled Project, which includes data from case-control studies in the United States and Canada (1690 cases/5131 controls). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.envint.2019.03.018DOI Listing
March 2019
3 Reads

Therapy-related myeloid neoplasms in lymphoma survivors: Reducing risks.

Best Pract Res Clin Haematol 2019 03 16;32(1):47-53. Epub 2019 Feb 16.

Massey Cancer Center, Virginia Commonwealth University, Richmond VA, United States. Electronic address:

Treatment for Hodgkin (HL) and non-Hodgkin's lymphoma (NHL) has changed dramatically in the last fifty years. While there are increasing numbers of long-term survivors, there has been increasing recognition of the long-term toxicities of treatments, particularly therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML). The survival for t-MDS/AML is extremely poor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2019.02.008DOI Listing
March 2019
1 Read

Treatment modalities of non-Hodgkin lymphoma patients over 65 years of age: A two-center experience.

J Oncol Pharm Pract 2019 Mar 29:1078155219839460. Epub 2019 Mar 29.

9 Department of Biostatistics and Medical Informatics, Bezmialem Vakif University, Istanbul, Turkey.

Objective: This study was conducted with the aim of making the contribution to a decision for treatment and determination of the modalities in patients diagnosed with non-Hodgkın lymphoma which increasingly become widespread in the geriatric population.

Materials And Methods: Ninety-one patients aged over 65 years diagnosed with lymphoma and treated in Bezmialem Vakıf University Medical Faculty Hospital and Haseki Training and Research Hospital between 2008 and 2013 were retrospectively evaluated. Finally, 63 patients for whom data could be reached were included in the study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1078155219839460DOI Listing
March 2019
1 Read

Hematuria Alone or in Combination with Proteinuria Is a Harbinger of Poor Prognosis in Patients with Non-Hodgkin Lymphoma.

Nephron 2019 Mar 28:1-8. Epub 2019 Mar 28.

Department IV, Internal Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Background: Screening for hematuria is essential during health checkups in the general population. However, urine examinations in patients with cancer tend to be overlooked. This study attempted to demonstrate the novel utility of urinalysis in the assessment of the prognosis of non-Hodgkin lymphoma (NHL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000499081DOI Listing
March 2019
2 Reads

Second cancers and causes of death in patients with testicular cancer in Sweden.

PLoS One 2019 28;14(3):e0214410. Epub 2019 Mar 28.

Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

While treatment for testicular cancer (TC) has become standardized after the 1980s with an associated significant improvement in patient survival, this has been accompanied by an increased risk of second primary cancers (SPCs). Patients were identified from the Swedish Cancer Registry spanning the years from 1980 to 2015, including 8788 individuals with primary TC and their SPCs. Relative risks (RRs) for SPC were calculated using the generalized Poisson regression model. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0214410PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438485PMC
March 2019
1 Read